Rezolute, Inc.
RZLTHealthcareNASDAQBiotechnology · Last scanned May 28, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 27
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. With a market capitalization of $319.7M, it sits in small-cap territory. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
Market Cap
$319.7M
Beta
0.67
P/E (TTM)
—
P/E (Fwd)
-5.25
EPS (TTM)
$-0.81
EPS (Fwd)
$-0.63
ROE
-81.7%
ROA
-48.7%
Cash
$120.3M
Total Debt
$1.1M
Free CF
-$43.7M
52W Change
-20.1%
Annual Financials
Cash vs Debt
With $120.3M in cash and $1.1M in debt, RZLT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$43.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -81.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.67 suggests RZLT is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, RZLT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Rezolute, Inc. and its sector.